Engineered exosome for targeting Alzheimer's disease focus and removing beta-amyloid plaque as well as preparation method and application of engineered exosome

By using the combination of photothermal nanoparticles and hybrid exosomes in Alzheimer's treatment, the problems of low drug delivery efficiency and insufficient targeting are solved, and efficient targeting of Alzheimer's lesions are achieved Treatment and neuronal viability recovery.

CN118949069AActive Publication Date: 2024-11-15HUNAN UNIV

Patent Information

Application Number
CN202411043257.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

Due to poor biocompatibility and low permeability of the blood-brain barrier, existing Alzheimer's disease treatment drugs are difficult to effectively pass through the blood-brain barrier, and the targeting and function of exosomes in the treatment are single, so they cannot effectively interfere with the lesions.

Method used

Photothermal nanoparticles are used as the nucleus of engineered exosomes, hybrid exosomes are synthesized through membrane fusion technology, and Aβ recognition probes are modified on their surface to load small molecule drugs, improve drug delivery efficiency and targeting, and use Photothermal depolymerization of beta amyloid protein promotes microglia to remove Aβ and reduces inflammatory response.

Benefits of technology

It has achieved efficient and low-toxic drug delivery to brain injury sites, enhanced the targeted and multi-target intervention capabilities of Alzheimer's lesions, promoted the recovery of neuronal vitality, and provided a new therapeutic strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949069A_ABST
    Figure CN118949069A_ABST
Patent Text Reader

Abstract

The invention provides an engineered exosome for targeting an Alzheimer's disease focus and removing beta amyloid plaque as well as a preparation method and application of the engineered exosome. The engineered exosome takes photo-thermal nanoparticles as a core of the engineered exosome; a hybrid exosome formed by fusing a brain microvascular endothelial cell exosome and a macrophage exosome is used as a shell-core structure of a shell, an A beta recognition probe is modified on the surface of the shell-core structure, and a small molecule drug is loaded in the shell-core structure. The preparation method comprises the following steps: mixing photo-thermal nanoparticles with a small molecule drug solution, incubating overnight, adding a brain microvascular endothelial cell exosome and a macrophage exosome, and carrying out ultrasonic treatment and incubation to obtain a hybrid exosome loaded with the photo-thermal nanoparticles and the small molecule drug; and adding an A beta recognition probe for incubation and centrifugation. The engineered exosome provided by the invention has good biocompatibility, relatively high blood brain barrier permeability, focus site targeting and multi-target intervention capability, and can be used for treating Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to an engineered exosome that targets Alzheimer's disease lesions and removes beta-amyloid plaques, and a preparation method and application thereof. Background Art

[0002] Alzheimer's disease (AD) is a neurodegenerative disease. According to statistics, about 55 million people suffer from AD worldwide. However, there is still no effective way to cure AD. This may be due to the complex pathogenesis of AD. The therapeutic drugs targeting a single pathogenic factor are not enough to improve the multifaceted pathological changes associated with AD. Therefore, the development of multifunctional AD therapeutic drugs has important practical significance.

[0003] Due to the special structure and function of the blood-brain barrier (BBB), most therapeutic drugs cannot effectively penetrate the BBB, which has a negative impact on the bioavailability and therapeutic effect of the drugs. Most existing work uses synthetic nanoparticles (such as gold-based nanomaterials, carbon materials, and polymers) as drug delivery carriers to treat AD. However, these nanoparticles generally have problems such as complex synthesis, poor biocompatibility, easy induction of immune response, and poor BBB permeability, which limits their further application in vivo. Therefore, it is imperative to develop drug delivery carriers with good biocompatibility and BBB permeability.

[0004] As an endogenous extracellular vesicle, exosomes have the ability to serve as drug delivery carriers due to their natural vesicle structure. Compared with other synthetic nanoparticle drug carriers, exosomes have lower immunogenicity and toxicity, and have the ability to naturally cross the BBB to deep brain tissue. In addition, some exosomes can migrate in a directional manner with the help of their own membrane surface receptors or extracellular matrix binding proteins to be recognized and taken up by specific receptor cells, making them a promising brain drug delivery carrier. Studies have found that after systemic administration, exosomes are mainly non-specifically enriched in the spleen and liver. Although some exosomes have the effect of intervening in the development of the disease, their functions are relatively simple. It can be seen that it is far from enough to rely solely on the intrinsic characteristics of exosomes to develop exosome-based treatments. Therefore, it is urgent to carry out reasonable engineering design and modification of exosomes to meet the needs of AD intervention, and obtain engineered exosomes with specific functions to achieve effective intervention in AD. Summary of the invention

[0005] The technical problem to be solved by the present invention is to overcome the problems of poor biocompatibility and low BBB permeability of anti-AD drugs or delivery carriers in the prior art, as well as the shortcomings of exosomes in AD treatment, such as poor targeting and single function, and to provide an engineered exosome that targets Alzheimer's lesions and clears β-amyloid plaques, and a preparation method and application thereof. The engineered exosome has good biocompatibility, high BBB permeability, lesion site targeting and multi-target intervention capabilities.

[0006] The technical solution adopted by the present invention to solve the technical problem is:

[0007] Photothermal nanoparticles are used as the core of engineered exosomes, giving the engineered exosomes good photothermal properties, enabling controllable release of loaded drugs and photothermal disaggregation of amyloid β (Aβ) aggregates. The natural homing effect of brain microvascular endothelial cell exosomes and the natural inflammatory tropism of macrophage exosomes are utilized to fuse the two exosomes through membrane fusion technology to obtain hybrid exosomes, and the hybrid exosomes are used as the outer shell and the Aβ recognition probe is modified on its surface through membrane targeted modification technology, avoiding the influence of modification density and steric hindrance when modifying two or more ligands on the exosomes, thereby improving the BBB penetration ability of the engineered exosomes and the enrichment level of the lesion site (inflammatory areas and Aβ aggregate-enriched areas in the brain). In addition, small molecule drugs are simultaneously loaded into the exosome cavity and the natural phospholipid bilayer of the exosome membrane to increase the drug loading capacity of the engineered exosomes, and deliver therapeutic drugs to the damaged site of the brain in an efficient and low-toxic manner. The engineered exosomes restore microglial function by promoting microglial clearance of Aβ, scavenging reactive oxygen species and reducing nitric oxide synthase (iNOS) expression, and photothermally disaggregate Aβ aggregates and restore neuronal vitality, providing a new strategy for AD treatment and laying a systematic and scientific foundation for the application of engineered exosomes in AD treatment.

[0008] The present invention provides an engineered exosome that targets Alzheimer's disease lesions and clears beta-amyloid plaques, wherein the engineered exosome comprises photothermal nanoparticles, hybrid exosomes, Aβ recognition probes and small molecule drugs; the engineered exosomes use photothermal nanoparticles as the core of the engineered exosomes and the hybrid exosomes as the shell to form a shell-core structure, the Aβ recognition probe is modified on the surface of the shell-core structure, and the small molecule drug is loaded in the cavity and / or the natural phospholipid bilayer of the membrane of the engineered exosomes; the hybrid exosomes are obtained by membrane fusion of brain microvascular endothelial cell exosomes and macrophage exosomes.

[0009] In the above-mentioned engineered exosomes, further, the photothermal nanoparticles are one of polydopamine nanoparticles, diketopyrrolopyrrole polymers, gold nanorods, black phosphorus nanomaterials and copper sulfide nanoparticles.

[0010] In the above-mentioned engineered exosomes, further, the small molecule drug is one or more of resveratrol, curcumin, and quercetin.

[0011] In the above-mentioned engineered exosomes, further, the brain microvascular endothelial cells are bEnd.3 cells; and the macrophages are RAW264.7 cells.

[0012] In the above-mentioned engineered exosomes, further, the Aβ recognition probe is an Aβ nucleic acid aptamer, an antibody or a polypeptide;

[0013] The gene sequence of the Aβ nucleic acid aptamer is shown in SEQ ID NO.1;

[0014] The antibody is 1F12;

[0015] The polypeptide is one of KLVFF, KLVFFADE, LPFFD and LVFFA.

[0016] In the above-mentioned engineered exosomes, further, the Aβ recognition probe is labeled with cholesterol.

[0017] In the above-mentioned engineered exosomes, further, the mass ratio of the photothermal nanoparticles to the small molecule drug is 1 to 4:1.

[0018] The above-mentioned engineered exosomes, further, the weight ratio of the brain microvascular endothelial cell exosomes to the macrophage exosomes is 1:1.

[0019] The above-mentioned engineered exosomes, further, the mass ratio of the hybrid exosomes to the photothermal nanoparticles is 1:1.

[0020] Based on a general technical concept, the present invention also adopts a method for preparing the engineered exosomes, comprising the following steps:

[0021] S1, mixing the photothermal nanoparticles with the small molecule drug solution, and incubating overnight to obtain a mixed solution;

[0022] S2, adding brain microvascular endothelial cell exosomes and macrophage exosomes to the mixed solution, performing ultrasound and incubation to obtain hybrid exosomes loaded with photothermal nanoparticles and small molecule drugs;

[0023] S3. Add Aβ recognition probe for incubation, and obtain engineered exosomes after centrifugation.

[0024] In the above preparation method, further, the ultrasonic conditions in S2 are: 100W ultrasonic for 2 seconds with an interval of 2 seconds, for 10 minutes under ice bath conditions; and the incubation conditions are: 37°C, static incubation for 1 hour.

[0025] In the above preparation method, further, the incubation time in S3 is 30 minutes and the incubation temperature is 37°C.

[0026] Based on a general technical concept, the present invention also provides a use of the engineered exosomes in the preparation of drugs that target Alzheimer's disease lesions and / or clear β-amyloid plaques.

[0027] Based on a general technical concept, the present invention also provides an application of the engineered exosomes in the preparation of a drug that promotes microglia to clear Aβ aggregates.

[0028] Based on a general technical concept, the present invention also provides a use of the engineered exosomes in the preparation of a drug for removing reactive oxygen species in microglia and reducing the expression of iNOS in microglia.

[0029] Based on a general technical concept, the present invention also provides an application of the engineered exosomes in the preparation of a drug for photothermal depolymerization of Aβ aggregates and restoration of neuronal vitality.

[0030] The engineered exosomes of the present invention have high BBB permeability, can target Aβ aggregates and inflammatory sites in AD brain lesions, reduce nonspecific losses, and have enhanced multi-targeting capabilities.

[0031] The engineered exosomes of the present invention can promote microglia to clear Aβ, restore microglia function by clearing reactive oxygen and reducing iNOS expression, disaggregate Aβ aggregates by photothermal method and restore neuronal vitality.

[0032] Compared with the prior art, the advantages of the present invention are:

[0033] The present invention provides an engineered exosome, which is safe, non-toxic, and has high biocompatibility, and can solve the problems of low efficacy, large adverse reactions, and low drug delivery efficiency of AD therapeutic drugs. The preparation process of the engineered exosomes obtained after engineering the exosomes is simple and mature, and has the function of protecting the loaded drugs from phagocytosis and uptake by immune cells. It can penetrate the BBB, target Aβ aggregates and inflammatory sites in the brain, and deliver therapeutic drugs to the brain in an efficient and low-toxic manner, realizing multi-target combined treatment of AD. This method provides a new strategy for the treatment of AD. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to make the purpose, technical solution and advantages of the embodiments of the present invention more clear, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0035] Figure 1The synthesis pathway of engineered exosomes and their mechanism of action in targeting Alzheimer's disease lesions and removing β-amyloid plaques in Example 1 of the present invention

[0036] Figure 2 This is a TEM characterization image of the engineered exosomes in Example 1 of the present invention.

[0037] Figure 3 This is a DLS characterization diagram of the engineered exosomes in Example 1 of the present invention.

[0038] Figure 4 This is a CLSM characterization diagram of the engineered exosomes in Example 1 of the present invention.

[0039] Figure 5 This is a characterization diagram of the ultraviolet absorption spectrum of the engineered exosomes in Example 1 of the present invention.

[0040] Figure 6 This is the SDS-PAGE characterization diagram of the engineered exosomes in Example 1 of the present invention.

[0041] Figure 7 This is a diagram showing the photothermal property identification results of engineered exosomes in Example 1 of the present invention.

[0042] Figure 8 This is a graph showing the results of identifying the release rate of resveratrol in engineered exosomes in Example 1 of the present invention.

[0043] Fig. 9 This is a diagram showing the results of identifying the ability of engineered exosomes to escape macrophage phagocytosis in Example 1 of the present invention.

[0044] Fig.10 This is a diagram showing the results of the identification of the BBB penetration performance of engineered exosomes in Example 1 of the present invention.

[0045] Fig.11 This is a diagram showing the results of the performance identification of engineered exosomes targeting inflammatory sites in Example 1 of the present invention.

[0046] Fig.12 This is a diagram showing the results of the identification of the performance of engineered exosomes targeting Aβ in Example 1 of the present invention.

[0047] Fig.13 This is a graph showing the results of identifying the ability of engineered exosomes to promote microglia to clear Aβ aggregates in Example 2 of the present invention.

[0048] Fig.14 This is a diagram showing the results of identifying the effects of engineered exosomes in removing reactive oxygen species in microglia cells in Example 3 of the present invention.

[0049] Fig.15 This is a graph showing the immunofluorescence staining results of Example 3 of the present invention showing that engineered exosomes reduce the expression of iNOS in microglia.

[0050] Fig.16 This is the AFM imaging and ThT fluorescence identification results of the in vitro photothermal disaggregation of Aβ aggregates by engineered exosomes in Example 4 of the present invention.

[0051] Fig.17 This is a diagram showing the results of identifying the ability of engineered exosomes to decompose Aβ aggregates at the cellular level according to Example 4 of the present invention.

[0052] Fig.18 This is a graph showing the results of identifying the ability of engineered exosomes to restore neuronal vitality in Example 4 of the present invention.

[0053] Fig.19 This is a diagram showing the results of identifying the effect of engineered exosomes in clearing Aβ-induced reactive oxygen species in SH-SY5Y cells according to Example 4 of the present invention. DETAILED DESCRIPTION

[0054] The present invention is further described below in conjunction with specific preferred embodiments, but the protection scope of the present invention is not limited thereby.

[0055] The materials, reagents and instruments used in the following examples can all be purchased from commercial channels. The experimental methods in the following examples, unless otherwise specified, are all conventional methods in the art. Among them, dopamine hydrochloride was purchased from Bailingwei Technology Co., Ltd.; resveratrol was purchased from Aladdin Reagent (Shanghai) Co., Ltd.; cholesterol-labeled Aβ nucleic acid aptamer was synthesized by Shanghai Bioengineering Co., Ltd.; amyloid protein Aβ was purchased from Gill Biochemical (Shanghai) Co., Ltd.; iNOS antibody and CoraLite 647-labeled goat anti-rabbit secondary antibody were purchased from Proteintech; reactive oxygen detection kit was purchased from Biyuntian Biotechnology Co., Ltd.; FITC was purchased from Beijing Solebao Technology Co., Ltd.; thioflavin T (ThT) was purchased from Sigma; human neuroblastoma cell line SH-SY5Y was purchased from China Center for Type Culture Collection; bEnd.3 cell line and RAW264.7 cell line were purchased from the Cell Bank of the Chinese Academy of Sciences.

[0056] Example

[0057] An engineered exosome that targets Alzheimer's disease lesions and clears amyloid β plaques, with photothermal nanoparticles as the core of the engineered exosome, and a shell-core structure with a hybrid exosome formed by the fusion of brain microvascular endothelial cell exosomes and macrophage exosomes as the outer shell, Aβ recognition probes modified on the surface of the shell-core structure, and small molecule drugs loaded in the exosome cavity and the natural phospholipid bilayer of the exosome membrane.

[0058] Figure 1The synthetic pathway of engineered exosomes and their mechanism of action for targeting Alzheimer's disease lesions and clearing amyloid-β plaques. As can be seen from the figure: brain microvascular endothelial cell exosomes have a natural blood-brain barrier homing effect, and macrophage exosomes have a natural inflammatory tendency. The two exosomes are fused by membrane fusion technology to obtain hybrid exosomes, which can easily cross the blood-brain barrier. Aβ recognition probes are modified on its surface by membrane targeted modification technology. Aβ recognition probes can bind to Aβ plaques in the brain, capture Aβ aggregates and enrich in the inflammatory site of the brain, which can avoid the influence of modification density and steric hindrance when modifying multiple ligands on exosomes, and enhance the BBB penetration ability of engineered exosomes and the ability to target inflammatory areas and Aβ plaques in the brain. The photothermal properties of photothermal nanoparticles can disaggregate Aβ aggregates and controllably release small molecule drugs.

[0059] Therefore, the engineered exosomes of the present invention can effectively intervene in AD through multiple pathways, including: ① promoting microglia to clear Aβ and reduce the Aβ load in the brain; ② downregulating iNOS expression and clearing reactive oxygen species to normalize microglial function; ③ photothermal depolymerization of toxic Aβ aggregates, thereby enhancing neuronal activity.

[0060] Furthermore, the photothermal nanoparticles are one or more of polydopamine nanoparticles, diketopyrrolopyrrole polymers, gold nanorods, black phosphorus nanomaterials, and copper sulfide nanoparticles. The function of the photothermal nanoparticles is to disaggregate Aβ aggregates and controllably release small molecule drugs, so nanoparticles with photothermal properties can produce the same or similar technical effects.

[0061] Furthermore, the small molecule drug is one or more of resveratrol, curcumin, and quercetin. The function of small molecule drugs is to remove reactive oxygen species and relieve neuroinflammation.

[0062] Furthermore, the brain microvascular endothelial cells are bEnd.3 cells; and the macrophages are RAW264.7 cells.

[0063] Furthermore, the Aβ recognition probe is an Aβ nucleic acid aptamer, antibody or peptide;

[0064] The gene sequence of the Aβ nucleic acid aptamer is shown in SEQ ID NO.1;

[0065] The antibody is 1F12;

[0066] The polypeptide is one of KLVFF, KLVFFADE, LPFFD and LVFFA.

[0067] Furthermore, the Aβ recognition probe is labeled with cholesterol. The effect of cholesterol labeling is that cholesterol, as a lipophilic cross-linking agent, can be anchored and inserted into the phospholipid bilayer of the exosome, so that the recognition probe is stably retained on the exosome membrane.

[0068] Example 1

[0069] An engineered exosome that targets Alzheimer's disease lesions and removes amyloid beta plaques is a core-shell structure with polydopamine nanoparticles (PDA) as the core of the engineered exosome and a hybrid exosome as the shell. The hybrid exosome is obtained by fusing exosomes from brain microvascular endothelial cells (bEnd.3 cells) and exosomes from macrophages (RAW264.7 cells). A cholesterol-labeled Aβ recognition probe is modified on the surface of the core-shell structure, and a small molecule drug: resveratrol (Res) is loaded in the exosome cavity and the natural phospholipid bilayer of the exosome membrane. Res can remove reactive oxygen species and relieve neuroinflammation.

[0070] The sequence of the cholesterol-labeled Aβ recognition probe (chol-Apt40) is shown in SEQ ID NO. 1, specifically: 5'-TTTTTTTTGCTGCCTGTGGTGTTGGGGCGGGTGCG-3'.

[0071] The preparation method comprises the following steps:

[0072] (1) Extraction of exosomes from brain microvascular endothelial cells and macrophages.

[0073] 1.1. Preparation of exosome-free DMEM complete medium: Exosomes were removed from fetal bovine serum (FBS) by ultracentrifugation (100,000 × g, 4 ° C, 4 h), and the precipitate was removed to obtain exosome-free serum. The exosome-free serum was then used to prepare DMEM complete medium, which contained 10% exosome-free FBS and 1% penicillin-streptomycin by volume.

[0074] 1.2. Obtain a culture medium rich in brain microvascular endothelial cell exosomes and macrophage exosomes: Use DMEM containing 10% fetal bovine serum as the culture medium, culture brain microvascular endothelial cells and macrophages at 37°C, 5% CO2. When the cells grow to 60% of the culture dish by adhesion, switch to exosome-free DMEM complete culture medium and continue to culture at 37°C for 48 hours. Then, collect the culture medium of the two cells into centrifuge tubes respectively to obtain a culture medium rich in brain microvascular endothelial cell exosomes (bEnd.3Exo) and macrophage exosomes (RAW 264.7Exo).

[0075] 1.3. Extract exosomes: centrifuge at 4°C, 2000×g for 10 min to remove dead cells, centrifuge the supernatant at 10,000×g for 60 min to remove cell debris, filter the supernatant through a 0.22μm filter to remove microvesicles with a diameter greater than 200nm, centrifuge at 100,000×g for 70 min, discard the supernatant, add appropriate amount of PBS to resuspend the precipitate at the bottom of the tube to obtain bEnd.3Exo and RAW 264.7Exo, and store at -80°C for future use.

[0076] (2) Synthesis of PDA: 90 mL of ultrapure water, 40 mL of anhydrous ethanol and 3 mL of aqueous ammonia were added to a reaction bottle in sequence and magnetically stirred at 30°C for 30 min. 10 mL of a 50 mg / mL aqueous dopamine hydrochloride solution was added to the stirred solution. Stirring was continued for 24 h, and the precipitate was collected by centrifugation at 12,000 rpm. The precipitate was purified with deionized water to obtain PDA, which was freeze-dried and weighed for later use.

[0077] (3) Preparation of engineered exosomes:

[0078] 3.1. Mix 200 μg / mL PDA and 80 μg / mL Res solution and incubate overnight, add bEnd.3Exo and RAW 264.7Exo (weight ratio of bEnd.3Exo and RAW 264.7Exo 1:1, 200 μg / mL), and treat with ultrasound (100 W, ultrasound for 2 seconds with an interval of 2 seconds) for 10 minutes under ice bath conditions to fuse the two exosome membranes and load PDA and Res therein. After incubation at 37°C for 1 hour, centrifuge and wash, and collect the precipitate.

[0079] 3.2. Resuspend the precipitate in PBS solution (keep the PDA concentration at 200 μg / mL), add cholesterol-labeled chol-Apt40 (600 nM), incubate at 37°C with shaking at 300 rpm for 30 min, and collect the precipitate after centrifugation and washing.

[0080] 3.3. Resuspend the precipitate in PBS solution to obtain engineered exosomes (RPDA@Rb-A) that target Alzheimer's disease lesions and clear β-amyloid plaques.

[0081] Experiment 1: Characterization of RPDA@Rb-A.

[0082] 1.1 TEM characterization.

[0083] The morphology of RPDA@Rb-A was characterized by transmission electron microscopy (TEM). Figure 2: It can be observed from the figure that the morphology of the two exosomes is cup-shaped, which proves the successful extraction of exosomes; PDA is spherical and well dispersed; from the characterization image of RPDA@Rb-A, it can be observed that there is obvious membrane coating on PDA, which presents a typical core-shell structure, indicating the successful synthesis of engineered exosomes.

[0084] 1.2. DLS characterization.

[0085] The sizes of PDA, PDA@Rb and RPDA@Rb-A were determined by dynamic light scattering (DLS). Figure 3 :It can be observed from the figure that the particle sizes of PDA, RPDA@Rb (engineered exosomes without chol-Apt40 modification) and RPDA@Rb-A are 86.61±5.16nm, 108.67±6.32nm, and 117.37±4.58nm, respectively. PDA@Rb is about 22nm larger than PDA, indicating that PDA is successfully encapsulated by exosomes. RPDA@Rb-A is about 8nm larger than RPDA@Rb, indicating the successful modification of chol-Apt40 on the surface of PDA@Rb, proving the successful synthesis of engineered exosomes.

[0086] 1.3. CLSM characterization.

[0087] RAW 264.7Exo and bEnd.3Exo were labeled with Dil and DiD dyes, respectively, and confocal laser scanning microscopy (CLSM) was used to verify the fusion of the two exosome membranes. Figure 4 : As can be seen from the figure, RAW 264.7Exo and bEnd.3Exo exhibit green and red fluorescence, respectively; when RAW 264.7Exo and bEnd.3Exo are fused at a protein weight ratio of 1:1, it can be observed that RPDA@Rb-A exhibits obvious fluorescence colocalization, indicating the successful fusion of the two exosome membranes.

[0088] 1.4. Ultraviolet absorption spectrum characterization.

[0089] The engineered exosomes were characterized by UV absorption spectroscopy, and the results are shown in Figure 5 : It can be seen from the figure that the UV absorption spectrum of RPDA@Rb-A has the characteristic absorption peaks of both PDA and Res, which can further prove the successful synthesis of engineered exosomes.

[0090] 1.5. SDS-PAGE characterization.

[0091] Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyze the protein spectrum of exosomes in RPDA@Rb-A and compared with RAW 264.7Exo, bEnd.3Exo and hybrid exosomes (Rb). Figure 6 : It can be seen from the figure that RPDA@Rb-A matches the protein bands of the two exosomes and hybrid exosomes, indicating that PDA is successfully encapsulated by exosomes and may have the same biological functions as exosomes, proving the successful synthesis of engineered exosomes.

[0092] Experiment 2: Investigation of the photothermal properties of engineered exosomes.

[0093] RPDA@Rb-A was diluted to different concentrations and illuminated by 808 nm near-infrared laser (1.0 W / cm 2 ) for 10 min, the temperature changes over time were recorded, and the photothermal stability of RPDA@Rb-A was evaluated by on / off cycle irradiation experiments.

[0094] Figure 7 The results of the photothermal properties identification of engineered exosomes; Figure A shows the temperature change of different concentrations of RPDA@Rb-A under near-infrared (NIR) light, and Figure B shows the photothermal stability results. It can be seen from the figure that compared with aqueous solution, different concentrations of RPDA@Rb-A at 1.0W / cm 2 Under NIR light, the temperature can be seen to rise significantly, indicating that the engineered exosomes have good photothermal conversion ability. During the four cycles of irradiation, the four temperature peaks of the RPDA@Rb-A solution were 44.9°C, 44.6°C, 44.2°C, and 44.1°C, showing only slight differences, indicating that the engineered exosomes have good photothermal stability.

[0095] Experiment 3: Identification of the release rate, encapsulation efficiency and loading capacity of resveratrol in engineered exosomes.

[0096] RPDA@Rb-A was placed in a dialysis bag (MWCO = 3500Da), immersed in 50mL PBS (containing 1% w / v Tween80), and stirred at 37°C (100rpm). At the specified time interval, 1mL was taken each time and 1mL of the system was added. In the NIR light irradiation group, near-infrared laser (808nm, 1.0W / cm 2 )Irradiate the sample for 20 min.

[0097] Figure 8The concentration of Res was determined by UV-visible absorption spectroscopy. It can be seen from the figure that the cumulative release of Res in RPDA@Rb-A was 42% at 28h. After near-infrared laser irradiation, the release rate of Res can be increased to 64%, indicating that the engineered exosomes can achieve controlled release of drugs under near-infrared light, reduce the toxic side effects of drugs on normal tissues and cells, and increase the enrichment concentration of drugs in the lesion site. The encapsulation performance of Res, the encapsulation rate and drug loading were 46.7% and 27.1%, respectively.

[0098] Experiment 4: Investigate the ability of engineered exosomes to evade macrophage phagocytosis.

[0099] RAW 264.7 cells were seeded in 24-well plates at a density of 4 × 10 5 Cells / well, 24 hours later, were incubated with FITC-labeled RPDA (PDA loaded with Res), RPDA@RA (RAW 264.7Exo coated with RPDA and modified with chol-Apt40), RPDA@bA (bEnd.3Exo coated with RPDA and modified with chol-Apt40) and RPDA@Rb-A for 4 hours. Cells were observed under CLSM. At the same time, the fluorescence intensity of cells was quantified by flow cytometry.

[0100] Fig. 9 The figure shows the results of the identification of the ability of engineered exosomes to evade macrophage phagocytosis. A in the figure is the CLSM result, and B and C in the figure are the results of the fluorescence intensity of the cells quantified by flow cytometry. It can be seen from the figure that compared with the significant green fluorescence signal in the cytoplasm after PDA treatment, almost no fluorescence signal was observed in the cells treated with RPDA@Rb-A, indicating that the engineered exosomes have the potential to evade immune clearance. The results of flow cytometry analysis showed that the fluorescence intensity of cells treated with RPDA@Rb-A was significantly weakened compared with that of cells treated with RPDA, further confirming this result.

[0101] Experiment 5: Investigate the ability of engineered exosomes to penetrate the BBB.

[0102] bEnd.3 cells were inoculated into the upper chamber of the Transwell plate and cultured until a dense cell monolayer was formed to form an in vitro BBB model. The culture medium in the upper chamber was then discarded, and DMEM culture medium containing FITC-labeled RPDA, RPDA@RA, RPDA@bA, and RPDA@Rb-A was added, and the effect of NIR illumination on the penetration performance of RPDA@Rb-ABBB was investigated (RPDA@Rb-A+NIR). At different time points, the culture medium in the lower chamber was collected and the fluorescence intensity was measured using a fluorimeter.

[0103] Fig.10The results of the performance evaluation of engineered exosomes penetrating the BBB are shown in the figure. It can be seen from the figure that compared with RPDA, RPDA@Rb-A has a higher BBB penetration efficiency, and near-infrared laser irradiation can further enhance the ability of engineered exosomes to penetrate the BBB, and its penetration rate is about 1 times that of RPDA, indicating that the engineered exosomes have a higher BBB penetration rate.

[0104] Experiment 6: Investigate the performance of engineered exosomes in targeting inflammatory sites.

[0105] To evaluate the inflammatory tropism of engineered exosomes in vitro, BV2 cells were treated with Aβ aggregates for 12 h to simulate the cellular inflammatory microenvironment, and then incubated with FITC-labeled RPDA, RPDA@RA, RPDA@bA, and RPDA@Rb-A for 1 h, and the cells were observed by CLSM. At the same time, flow cytometry was used to quantify the fluorescence intensity of the cells.

[0106] Fig.11 The following is a graph showing the performance evaluation of engineered exosomes targeting inflammatory sites. A in the figure is the CLSM result, and B and C in the figure are the fluorescence intensity results of flow cytometry quantitative cells. It can be seen from the figure that RPDA@Rb-A only shows enhanced uptake in inflammatory cells, which is significantly higher than the uptake of RPDA. This shows that the engineered exosomes inherit the natural inflammatory targeting ability of macrophage exosomes and have the potential to accurately target inflammatory sites in brain lesions. The results of flow cytometry analysis are consistent with the CLSM results, further confirming this result.

[0107] Experiment 7: Investigate the performance of engineered exosomes in targeting Aβ.

[0108] Aβ monomers (AβM), Aβ oligomers (AβO), and Aβ fibrils (AβF) were incubated with RPDA@Rb or RPDA@Rb-A at room temperature for 1 h. Then, the mixture was centrifuged (12000 rpm, 10 min) to remove engineered exosomes and adsorbed Aβ. The concentration of Aβ in the supernatant was determined using a BCA kit.

[0109] Fig.12 The results of the identification of the performance of engineered exosomes targeting Aβ can be seen from the figure: RPDA@Rb-A modified with chol-Apt40 exhibits better targeting ability to Aβ aggregates (AβO and AβF).

[0110] Example 2

[0111] A use of the engineered exosomes of Example 1 in the preparation of a drug that promotes microglia to clear Aβ aggregates.

[0112] The application method is: 1×10 5BV-2 cells were seeded in confocal dishes, and after cell attachment, they were further incubated for 8 h with medium containing AβO in the presence or absence of PDA, RPDA, RPDA@Rb, RPDA@Rb-A, and RPDA@Rb-A+NIR (RPDA@Rb-A applied with near-infrared light). Then, FITC-AβO was used instead of AβO for another 4 h, and the cells were stained with LysoTracker Red and Hoechst 33342, and the effect of engineered exosomes on microglial phagocytosis of Aβ aggregates was observed by CLSM.

[0113] Fig.13 The results of the identification of the ability of engineered exosomes to promote microglial clearance of Aβ aggregates. As can be seen from the figure: more intense orange fluorescence was observed in microglia incubated with AβO and RPDA@Rb-A, indicating more co-localization of Aβ and lysosomes. It proves that engineered exosomes can promote Aβ clearance through the microglial lysosomal pathway.

[0114] Example 3

[0115] A use of the engineered exosomes of Example 1 in preparing a drug for removing reactive oxygen species in microglia and reducing iNOS expression in microglia.

[0116] Experiment 8: Engineered exosomes remove reactive oxygen species in microglia.

[0117] The application method is: 1×10 5 BV-2 cells were seeded in confocal dishes overnight. After the cells adhered, they were incubated with medium containing AβO in the presence or absence of PDA, RPDA, RPDA@Rb, RPDA@Rb-A, and RPDA@Rb-A+NIR for 24 hours. After washing the cells with PBS buffer, the DCFH-DA probe was added and incubated for 30 minutes, and the ROS content in the cells was observed by CLSM. The cells were seeded in 12-well plates and treated as described above. After incubation, the cells were washed three times with PBS buffer, collected after trypsin digestion, and dispersed in PBS after centrifugation and washing for flow cytometry detection.

[0118] Fig.14The following is a diagram showing the results of the identification of engineered exosomes in removing reactive oxygen species in microglia; A in the figure is the CLSM imaging result, and B and C in the figure are the flow cytometry analysis results. It can be seen from the figure that the cells with the addition of AβO showed strong fluorescence, indicating that a large amount of reactive oxygen species were produced in the cells with the addition of AβO. The fluorescence intensity did not change significantly after the addition of PDA and RPDA, but when RPDA@Rb and RPDA@Rb-A (with or without NIR illumination) were added, it was found that the fluorescence intensity in the cells was significantly reduced, indicating that the engineered exosomes have the ability to remove reactive oxygen species in cells. The flow cytometry analysis results are consistent with the CLSM results, further confirming this result.

[0119] Experiment 9: Engineered exosomes reduce iNOS expression in microglia.

[0120] The application method is: 1×10 5 BV-2 cells were seeded in confocal dishes. After the cells adhered, BV-2 cells were pretreated with AβO for 36 hours to induce the pro-inflammatory state of microglia. Then, they were incubated with PBS, PDA, RPDA, RPDA@Rb, RPDA@Rb-A and RPDA@Rb-A+NIR for 24 hours, fixed with methanol at -20°C for 5 minutes, permeated with 0.1% TritonX-100 for 15 minutes, blocked with 5% BSA for 30 minutes, incubated with iNOS antibody at 4°C overnight, washed with PBST and PBS three times, added with CoraLite 647-labeled goat anti-rabbit secondary antibody and incubated for 2 hours, washed with PBS, stained with DAPI staining solution at 37°C for 10 minutes, and imaged by CLSM.

[0121] Fig.15 The immunofluorescence staining results of engineered exosomes to reduce iNOS expression in microglia. It can be seen from the figure that the presence of AβO leads to increased iNOS expression, indicating the pro-inflammatory state of microglia. After treatment with RPDA@Rb-A, it can be observed that the expression of iNOS in the cells is significantly reduced, indicating that engineered exosomes can reduce the inflammatory response of microglia, inhibit microglial dysfunction, and accelerate Aβ clearance.

[0122] Example 4

[0123] A use of the engineered exosomes of Example 1 in preparing a drug for photothermal depolymerization of Aβ aggregates and restoring neuronal vitality.

[0124] Experiment 10: Investigate the photothermal disaggregation of Aβ aggregates by engineered exosomes in vitro.

[0125] AD is mainly caused by Aβ misfolding. To confirm the photothermal disaggregation of Aβ aggregates by engineered exosomes, the morphological changes of AβF after NIR irradiation were studied by atomic force microscopy (AFM). PBS, PDA, RPDA, RPDA@Rb, and RPDA@Rb-A were incubated with AβF for 24 h in the presence or absence of NIR (Aβ concentration was 50 μM, nanoparticle concentration was 200 μg / mL, and 808 nm laser power was 1.0 W / cm 2 , illumination time 10min). Then, the sample was dropped on fresh mica, and after drying, the morphological changes of AβF were observed using AFM. At the same time, the above samples were mixed with ThT solution. The fluorescence intensity of ThT was detected by a fluorescence instrument to evaluate its ability to depolymerize AβF.

[0126] Fig.16 The AFM imaging and ThT fluorescence identification results of the engineered exosomes in vitro photothermal depolymerization of Aβ aggregates. A in the figure is AFM imaging, and B and C in the figure are ThT fluorescence identification results. It can be seen from the figure that after adding RPDA@Rb-A and treating with NIR, the AβF structure is almost completely destroyed, proving the effectiveness of the 808nm near-infrared photothermal effect in decomposing Aβ aggregates. At the same time, when AβF treated with different treatments was mixed with ThT solution, the results of the RPDA@Rb-A and NIR group and the PBS group were basically the same. It shows that the engineered exosomes combined with near-infrared light show good function in decomposing AβF.

[0127] Experiment 11: Evaluate the ability of engineered exosomes to decompose Aβ aggregates at the cellular level.

[0128] SH-SY5Y cells were incubated with culture medium containing AβF in the presence or absence of PDA, RPDA, RPDA@Rb, RPDA@Rb-A, and RPDA@Rb-A+NIR for 24 h, and the ThT fluorescence intensity was observed by CLSM.

[0129] Fig.17 This is a result diagram of the ability of engineered exosomes to decompose Aβ aggregates at the cellular level. As can be seen from the figure: SH-SY5Y cells treated with AβF alone have strong ThT green fluorescence. When co-incubated with RPDA@Rb-A, ThT fluorescence was significantly reduced, and in the 808nm combined photothermal treatment group, the green fluorescence almost completely disappeared, indicating that the β-folded structure was almost completely destroyed, verifying the ability of engineered exosomes to decompose Aβ aggregates at the cellular level.

[0130] Experiment 12: Evaluate the ability of engineered exosomes to restore neuronal vitality.

[0131] Using Aβ-induced SH-SY5Y cell apoptosis as an AD experimental model, the therapeutic effect of engineered exosomes on AD was investigated at the cellular level. SH-SY5Y cells were seeded in a 96-well plate, and after the cells adhered, they were treated with AβF for 6 hours, and then PBS, PDA, RPDA, RPDA@Rb, and RPDA@Rb-A were added to the cells for further incubation with or without NIR for 24 hours. After treatment with MTT for 4 hours, 150μL DMSO was added to each well after removing the culture medium, and the samples were measured at 490nm using a microplate reader. The Aβ-induced cytotoxicity model was analyzed using the live / dead staining method, and SH-SY5Y cells were plated at 2×10 5 The cells were seeded at a density of 1.54 × 10 / dish in a 35 mm culture dish and incubated at 37°C for 24 h. Then, cells containing or not containing AβF and different materials were added and incubated for a further 24 h. The cells were stained with Calcein-AM / PI and photographed using CLSM.

[0132] Fig.18 This is the result of the identification of the ability of engineered exosomes to restore neuronal vitality. A in the figure is the result of the Calcein-AM / PI live-dead cell double staining experiment, B in the figure is the statistical analysis result of Figure A, and C in the figure is the cell survival rate under the conditions of with or without NIR. It can be seen from the figure that the survival rate of SH-SY5Y cells decreased to 43% after the action of AβF, while the cell survival rates increased to 65%, 71%, 83%, 85%, and 95% after the addition of PDA, RPDA, RPDA@Rb, RPDA@Rb-A, and RPDA@Rb-A+NIR, respectively, indicating that engineered exosomes can effectively inhibit Aβ-induced cytotoxicity and restore neuronal vitality. The Calcein-AM / PI live-dead cell double staining experiment also confirmed this result.

[0133] Experiment 13: Engineered exosomes clear Aβ-induced reactive oxygen species in SH-SY5Y cells.

[0134] 1×10 5 SH-SY5Y cells were seeded in confocal dishes overnight. After the cells adhered, they were incubated with medium containing AβF in the presence or absence of PDA, RPDA, RPDA@Rb, RPDA@Rb-A, and RPDA@Rb-A+NIR for 24 h. After the cells were washed with PBS buffer, the DCFH-DA probe was added and incubated for 30 min. The ROS content in the cells was observed by CLSM.

[0135] Fig.19The figure shows the results of the identification of engineered exosomes to remove reactive oxygen species in SH-SY5Y cells induced by Aβ. It can be seen from the figure that the fluorescence intensity of the RPDA@Rb-A treatment group is basically the same as that of the Control group, and is significantly lower than that of the AβF group. This shows that engineered exosomes can eliminate abnormal reactive oxygen species, maintain normal ROS levels in cells, and protect cells from Aβ-induced neural damage.

[0136] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as above in the preferred embodiment, it is not used to limit the present invention. Any technician familiar with the art can make many possible changes and modifications to the technical solution of the present invention by using the methods and technical contents disclosed above without departing from the spirit and technical solution of the present invention, or modify it into an equivalent embodiment of equivalent changes. Therefore, any simple modification, equivalent replacement, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention, still fall within the scope of protection of the technical solution of the present invention.

Claims

1. An engineered exosome that targets Alzheimer's disease lesions and removes amyloid β plaques, characterized in that: The engineered exosomes include photothermal nanoparticles, hybrid exosomes, Aβ recognition probes, and small molecule drugs; The engineered exosomes use photothermal nanoparticles as the core of the engineered exosomes and hybrid exosomes as the shell to form a shell-core structure, Aβ recognition probes are modified on the surface of the shell-core structure, and small molecule drugs are loaded in the natural phospholipid bilayer of the cavity and / or membrane of the engineered exosomes; the hybrid exosomes are obtained by fusion of brain microvascular endothelial cell exosomes and macrophage exosomes.

2. The engineered exosome according to claim 1, characterized in that The photothermal nanoparticles are one of polydopamine nanoparticles, diketopyrrolopyrrole polymers, gold nanorods, black phosphorus nanomaterials and copper sulfide nanoparticles; And / or, the small molecule drug is: one or more of resveratrol, curcumin, and quercetin; And / or, the brain microvascular endothelial cells are bEnd.3 cells; the macrophages are RAW264.7 cells; And / or, the Aβ recognition probe is an Aβ nucleic acid aptamer, an antibody or a polypeptide; The gene sequence of the Aβ nucleic acid aptamer is shown in SEQ ID NO.1; The antibody is 1F12; The polypeptide is one of KLVFF, KLVFFADE, LPFFD and LVFFA.

3. The engineered exosome according to claim 1, characterized in that The Aβ recognition probe is labeled with cholesterol.

4. The engineered exosome according to any one of claims 1 to 3, characterized in that The mass ratio of the photothermal nanoparticles to the small molecule drugs is 1-4:1, the mass ratio of the brain microvascular endothelial cell exosomes to the macrophage exosomes is 1:1; the mass ratio of the hybrid exosomes to the photothermal nanoparticles is 1:

1.

5. A method for preparing the engineered exosomes according to any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: S1, mixing the photothermal nanoparticles with the small molecule drug solution, and incubating overnight to obtain a mixed solution; S2, adding brain microvascular endothelial cell exosomes and macrophage exosomes to the mixed solution, performing ultrasound and incubation to obtain hybrid exosomes loaded with photothermal nanoparticles and small molecule drugs; S3. Add Aβ recognition probe for incubation, and obtain engineered exosomes after centrifugation.

6. The preparation method according to claim 5, characterized in that: The ultrasonic conditions in S2 are: 100W ultrasonic for 2 seconds with an interval of 2 seconds, for 10 minutes under ice bath conditions; the incubation conditions are: 37°C, static incubation for 1 hour; And / or, the incubation time in S3 is 30 min and the incubation temperature is 37°C.

7. Use of the engineered exosomes according to any one of claims 1 to 4 in the preparation of a drug for targeting Alzheimer's disease lesions and / or clearing β-amyloid plaques.

8. Use of the engineered exosomes according to any one of claims 1 to 4 in the preparation of a drug for promoting microglial cells to clear Aβ aggregates.

9. Use of the engineered exosomes according to any one of claims 1 to 4 in the preparation of a drug for removing reactive oxygen species in microglia and reducing the expression of iNOS in microglia.

10. Use of the engineered exosomes according to any one of claims 1 to 4 in preparing a drug for photothermal depolymerization of Aβ aggregates and restoration of neuronal vitality.

Citation Information

Patent Citations

  • Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease

    CN101076543A

  • Engineered exosome nano material as well as preparation method and application thereof

    CN114732905A

  • Bionic fusion membrane coated uricase, platinum nanoparticles and resveratrol lipid nanoparticles and preparation method thereof

    CN115531346A

  • Stable exosome nanoparticle targeting M2 type tumor-associated macrophages as well as preparation method and application of exosome nanoparticle

    CN116036042A

  • Dendrimer conjugates of small molecule biologics for intracellular delivery

    CN118043076A

Cited By

  • Targeted release nanoparticles loaded with mangosteen shell extract as well as preparation method and application of targeted release nanoparticles

    CN119679963A

  • A mangosteen shell extract-loaded targeted release nanoparticle, and a preparation method and application thereof

    CN119679963B

  • Therapeutic application of targeted exosome in improvement of blood-brain barrier destruction of acute ischemic stroke

    CN122057032A